Initial Evaluation of [18F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer

Zsolt Szabo, Esther Mena, Steven P. Rowe, Donika Plyku, Rosa Nidal, Mario A. Eisenberger, Emmanuel S. Antonarakis, Hong Fan, Robert F. Dannals, Ying Chen, Ronnie C. Mease, Melin Vranesic, Akrita Bhatnagar, George Sgouros, Steve Y. Cho, Martin G. Pomper

Research output: Contribution to journalArticlepeer-review

Abstract

Purpose: Prostate-specific membrane antigen (PSMA) is a recognized target for imaging prostate cancer. Here we present initial safety, biodistribution, and radiation dosimetry results with [18F]DCFPyL, a second-generation fluorine-18-labeled small-molecule PSMA inhibitor, in patients with prostate cancer. Procedures: Biodistribution was evaluated using sequential positron-emission tomography (PET) scans in nine patients with prostate cancer. Time-activity curves from the most avid tumor foci were determined. The radiation dose to selected organs was estimated using OLINDA/EXM. Results: No major radiotracer-specific adverse events were observed. Physiologic accumulation was observed in known sites of PSMA expression. Accumulation in putative sites of prostate cancer was observed (SUVmax up to >100, and tumor-to-blood ratios up to >50). The effective radiation dose from [18F]DCFPyL was 0.0139 mGy/MBq or 5 mGy (0.5 rem) from an injected dose of 370 MBq (10 mCi). Conclusions: [18F]DCFPyL is safe with biodistribution as expected, and its accumulation is high in presumed primary and metastatic foci. The radiation dose from [18F]DCFPyL is similar to that from other PET radiotracers.

Original languageEnglish (US)
Pages (from-to)565-574
Number of pages10
JournalMolecular Imaging and Biology
Volume17
Issue number4
DOIs
StatePublished - Aug 23 2015

Keywords

  • Fluorine-18
  • Molecular imaging
  • PET
  • PSMA
  • Prostate cancer

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Fingerprint

Dive into the research topics of 'Initial Evaluation of [<sup>18</sup>F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer'. Together they form a unique fingerprint.

Cite this